As the products of Daiwa Pharmaceutical Co., Ltd. (Setagaya-ku, Tokyo, Japan - President: Yasuo Ninomiya) are achieving a high reputation overseas, we will be starting actual sales in two Asian countries.

In India, we will tie up with Elder Pharmaceutical Ltd. (Mumbai, India - President: Saxena) and start marketing the main products BioBran and NKCP. Elder Pharmaceutical Ltd. is a drug manufacturing and distribution company established in 1989.

We look forward to broadening the market into Indian clinics and hospitals via Elder's distribution channel. India has many issues to be resolved; infection control, vitamin and mineral deficiency, etc. The idea of nutraceuticals has gradually spread throughout recent years.

Now supplements and functional food, unfamiliar earlier, are imported from overseas and distributed. In 2006, the Indian nutraceutical market is estimated to be US$5.25 billion and the number is rapidly increasing every year.

In China, Daiwa has tied up with Bangbo Pharm-Tech Co., Ltd. (Beijing) and started selling the main product BioBran. BioBran has been approved as a Supplement Food (Chinese version of Food for Specified Health Use: FOSHU) for its “immunopotentiating effect.” The approval obtained in a very short period is simply the result of highly valued Daiwa's 10-year sales performance and sufficient data.

BioBran will be on sale mainly in drug stores in China, with first year sales of \1.5billion (market price) expected. As two effects can be claimed for one supplement food in China, Daiwa is applying for approval of the additional effect “maintenance and treatment aid for drug-induced hepatitis.” NKCP, GABA and calcium may follow BioBran in the Chinese market.

・

Copyright(C)2006 Daiwa Pharmaceutical Co.,Ltd. All rights reserved. | HOME >